Global Information
회사소개 | 문의 | 비교리스트

과민성 방광 : 파이프라인 리뷰

Overactive Bladder - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 192758
페이지 정보 영문 127 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


과민성 방광 : 파이프라인 리뷰 Overactive Bladder - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 127 Pages

과민성 방광이란 방광의 축적 기능에 문제가 생겨 갑자기 요의를 느끼게 되는 질환입니다. 이 경우, 요의를 억제하기 어려우며 결과적으로 불수의적 배뇨(요실금)에 이르는 경우도 있습니다. 기타 증상으로 수면중 2-3회의 요의에 의한 기상도 들 수 있습니다. 주요 치료법으로 생활 습관의 개선 및 약물 치료에 의한 방광 활동 완화·요실금 방지 등을 들 수 있습니다.

세계 각국에서 과민성 방광 치료용 파이프라인 제품의 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 주요 기업의 개요, 주요 약제의 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

과민성 방광의 개요

치료제 개발

  • 과민성 방광용 파이프라인 제품 : 개요
  • 각 기업에서 개발중인 과민성 방광 치료제
  • 대학/연구기관에서 연구중인 과민성 방광 치료제
  • 과민성 방광 치료제 : 개발중인 제품 리스트(기업별)
  • 과민성 방광 치료제 : 연구중인 제품 리스트(대학/연구기관별)

과민성 방광 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

과민성 방광 치료제 개발에 참여하고 있는 기업

  • Addex Therapeutics Ltd
  • Allergan Plc
  • Asahi Kasei Pharma Corp
  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • Dong-A ST Co., Ltd.
  • FemmePharma Global Healthcare Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Hydra Biosciences Inc
  • Ion Channel Innovations LLC
  • Ipsen SA
  • Jeil Pharmaceutical Co Ltd
  • Juniper Pharmaceuticals Inc
  • Kissei Pharmaceutical Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lipella Pharmaceuticals Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • Ono Pharmaceutical Co Ltd
  • Recordati SpA
  • Roivant Sciences Ltd
  • Sanofi
  • Seoul Pharma Co Ltd
  • Taris Biomedical LLC
  • TheraVida Inc
  • Toray Industries Inc
  • XuanZhu Pharma Co Ltd

약제 개요

과민성 방광 치료제 : 개발이 휴지 상태인 제품

과민성 방광 치료제 : 개발이 중지된 제품

과민성 방광 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향·프레스 릴리스

부록

도표

KSA 17.05.30

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Overactive Bladder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Overactive Bladder - Pipeline by Aetas Pharma Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Allergan Plc, H1 2020
  • Overactive Bladder - Pipeline by Astellas Pharma Inc, H1 2020
  • Overactive Bladder - Pipeline by DelNova Inc, H1 2020
  • Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H1 2020
  • Overactive Bladder - Pipeline by Dong-A ST Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by DongKoo Bio & Pharma Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Evestra Inc, H1 2020
  • Overactive Bladder - Pipeline by Exxel Pharma Inc, H1 2020
  • Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H1 2020
  • Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Hydra Biosciences Inc, H1 2020
  • Overactive Bladder - Pipeline by Imbrium Therapeutics LP, H1 2020
  • Overactive Bladder - Pipeline by Ion Channel Innovations LLC, H1 2020
  • Overactive Bladder - Pipeline by J2H Biotech, H1 2020
  • Overactive Bladder - Pipeline by Johnson & Johnson, H1 2020
  • Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Korea United Pharm Inc, H1 2020
  • Overactive Bladder - Pipeline by KYORIN Holdings Inc, H1 2020
  • Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, H1 2020
  • Overactive Bladder - Pipeline by Medytox Inc, H1 2020
  • Overactive Bladder - Pipeline by Merck & Co Inc, H1 2020
  • Overactive Bladder - Pipeline by Mezzion Pharma Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by Recordati SpA, H1 2020
  • Overactive Bladder - Pipeline by Revance Therapeutics Inc, H1 2020
  • Overactive Bladder - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2020
  • Overactive Bladder - Pipeline by TheraVida Inc, H1 2020
  • Overactive Bladder - Pipeline by Velicept Therapeutics Inc, H1 2020
  • Overactive Bladder - Pipeline by XuanZhu Pharma Co Ltd, H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Overactive Bladder - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Overactive Bladder - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Overactive Bladder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2020, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 8, 3, 12, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Overactive Bladder - Overview
  • Overactive Bladder - Therapeutics Development
  • Overactive Bladder - Therapeutics Assessment
  • Overactive Bladder - Companies Involved in Therapeutics Development
  • Overactive Bladder - Drug Profiles
  • Overactive Bladder - Dormant Projects
  • Overactive Bladder - Discontinued Products
  • Overactive Bladder - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q